NCT07786441 KABAWIL: Reducing Intersectional Stigmas
| NCT ID | NCT07786441 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Washington |
| Condition | Stigma, Social |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 120 participants in total. It began in 2026-09-01 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to develop and test KABAWIL, a culturally tailored intervention designed to reduce HIV-related and intersectional stigmas experienced by Indigenous communities in Guatemala and improve engagement across the HIV Continuum of Care. The study will also assess the feasibility, acceptability, and implementation of the intervention. The main questions it aims to answer are: Can a culturally adapted version of the FRESH intervention reduce HIV-related and intersectional stigmas among Indigenous men and Indigenous healers? Does participation in KABAWIL improve outcomes related to HIV prevention, testing, treatment, and care using a status-neutral approach? Is KABAWIL feasible, acceptable, and appropriate for implementation in Indigenous communities in Guatemala? Researchers will first adapt the existing FRESH intervention through interviews and focus groups with Indigenous men, Indigenous healers, healthcare providers, stigma experts, and Maya knowledge keepers. Researchers will then compare participants who receive KABAWIL immediately with participants assigned to a 3-month wait-list control group. Participants will: Participate in interviews or focus groups to help adapt the intervention (Aim 1). Attend one of three KABAWIL workshops or be assigned to a 3-month wait-list control group (Aim 2). Complete surveys and assessments measuring HIV-related intersectional stigma and HIV Continuum of Care outcomes before and after the intervention (Aim 2). Participate in post-intervention interviews to provide feedback on the intervention's feasibility, acceptability, and implementation (Aim 3).
Eligibility Criteria
Inclusion Criteria: * 18 year of age and older * Self identifies as a man who has had sex with other men * Self identifies as traditional healer Exclusion Criteria: * Requires working knowledge of Spanish * Minor (under age 18)
Contact & Investigator
Roberto Orellana, PhD
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT07786441 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stigma, Social. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07786441 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07786441 currently recruiting?
Yes, NCT07786441 is actively recruiting participants. Contact the research team at popolvuh@uw.edu for enrollment information.
Where is the NCT07786441 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT07786441 clinical trial?
NCT07786441 is sponsored by University of Washington. The principal investigator is Roberto Orellana, PhD at University of Washington. The trial plans to enroll 120 participants.